Polypid Ltd (PYPD)

$4.39 +0.05 (1.15%)
Market Cap 70.11M
Revenue (ttm) 0.00
Net Income (ttm) -29.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.16
Volume 169,010
Avg Vol 80,228
Day's Range N/A - N/A
Shares Out 15.90M
Stochastic %K 15%
Beta 1.51
Analysts Strong Sell
Price Target $12.25

Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 4719 5700
Address:
18 Hasivim Street, Petah Tikva, Israel
aak12345
aak12345 Jan. 15 at 7:15 PM
$PYPD I see huge potential here (like 5x) over next 1 year.
0 · Reply
Finnish_boy
Finnish_boy Jan. 15 at 4:29 PM
$PYPD What's next? February: NDA rolling submission starts. March: US partnership deal, NDA submission. April: Label expansions talks with FDA May-June: GLP-1 platform data, NDA approval July-August: MAA submission late Q4- early 2027: FDA approval
0 · Reply
Finnish_boy
Finnish_boy Jan. 15 at 4:02 PM
$PYPD US partnership will be annoinced around NDA submission (March). Enough cash until FDA approval😍. What a setup. PT April $10. January-February nice time to buy more shares if SP stays under $5. Stock should be now already $10 !!
3 · Reply
Qesim
Qesim Jan. 15 at 4:00 PM
$PYPD Partnership in a matter of weeks.
0 · Reply
Finnish_boy
Finnish_boy Jan. 15 at 9:53 AM
$PYPD Today call. I will post if there is some new info.
0 · Reply
Finnish_boy
Finnish_boy Jan. 15 at 9:52 AM
$PYPD US partnership deal most likely in February, at the latest March. I was too early telling it's the matter of couple of weeks but when there is now multiple potential partners negotiating, that means bigger deal ! So patience now, and you will rewarded in a big way already in 2-3 months (US partnership + NDA submission)
1 · Reply
Finnish_boy
Finnish_boy Jan. 14 at 12:07 PM
$PYPD Phone app free. https://web.quartr.com/link/companies/17671/events/541547?targetTime=null
0 · Reply
Finnish_boy
Finnish_boy Jan. 14 at 11:56 AM
$PYPD
0 · Reply
Finnish_boy
Finnish_boy Jan. 12 at 5:31 PM
$PYPD 3 month target price: $10 !!
0 · Reply
Finnish_boy
Finnish_boy Jan. 12 at 5:29 PM
$PYPD Tomorrow event 👍we can hear hints about US partnership deal. Maybe they remind also about GLP-1 data and how they are progressing NDA submission. I think they will sign a deal with big med-device company Medtronic, J&J or BD in 1-7 weeks !! Buckle up !!
2 · Reply
Latest News on PYPD
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Dec 16, 2025, 8:30 AM EST - 4 weeks ago

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript

Dec 10, 2025, 4:42 PM EST - 5 weeks ago

PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

Dec 3, 2025, 8:30 AM EST - 6 weeks ago

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

Nov 25, 2025, 8:30 AM EST - 7 weeks ago

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

PolyPid Ltd. (PYPD) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:51 PM EST - 2 months ago

PolyPid Ltd. (PYPD) Q3 2025 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:30 AM EST - 2 months ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

Nov 6, 2025, 8:30 AM EST - 2 months ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Oct 29, 2025, 8:30 AM EDT - 2 months ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 30, 2025, 8:45 AM EDT - 3 months ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 8:44 AM EDT - 4 months ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 16, 2025, 8:30 AM EDT - 4 months ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 4 months ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Sep 2, 2025, 8:30 AM EDT - 4 months ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:52 PM EDT - 5 months ago

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 7:30 AM EDT - 5 months ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Aug 12, 2025, 8:00 AM EDT - 5 months ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Jul 30, 2025, 8:00 AM EDT - 6 months ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

Jul 15, 2025, 8:00 AM EDT - 6 months ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 16, 2025, 7:20 PM EDT - 7 months ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:42 AM EDT - 7 months ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 7 months ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 8:54 AM EDT - 7 months ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 9, 2025, 7:30 AM EDT - 7 months ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

Jun 6, 2025, 4:05 PM EDT - 7 months ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 30, 2025, 10:12 AM EDT - 8 months ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 20, 2025, 7:00 AM EDT - 8 months ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

May 14, 2025, 1:24 PM EDT - 8 months ago

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025, 7:00 AM EDT - 8 months ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 29, 2025, 7:00 AM EDT - 9 months ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

PolyPid to Participate in The Citizens Life Sciences Conference

Apr 22, 2025, 7:00 AM EDT - 9 months ago

PolyPid to Participate in The Citizens Life Sciences Conference

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 11, 2025, 7:00 AM EDT - 11 months ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Participate in the 37th Annual ROTH Conference

Mar 3, 2025, 7:00 AM EST - 11 months ago

PolyPid to Participate in the 37th Annual ROTH Conference

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 10:44 AM EST - 1 year ago

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 12, 2025, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Jan 29, 2025, 7:00 AM EST - 1 year ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

Dec 26, 2024, 10:31 AM EST - 1 year ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA AVXL

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 23, 2024, 7:22 PM EST - 1 year ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Dec 11, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 29, 2024, 1:05 PM EST - 1 year ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 2:06 PM EST - 1 year ago

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Nov 7, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 30, 2024, 8:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 21, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Participate in Three Upcoming Fall Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 1:25 PM EDT - 1 year ago

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

Aug 1, 2024, 8:31 PM EDT - 1 year ago

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

Jul 31, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

Jun 10, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

aak12345
aak12345 Jan. 15 at 7:15 PM
$PYPD I see huge potential here (like 5x) over next 1 year.
0 · Reply
Finnish_boy
Finnish_boy Jan. 15 at 4:29 PM
$PYPD What's next? February: NDA rolling submission starts. March: US partnership deal, NDA submission. April: Label expansions talks with FDA May-June: GLP-1 platform data, NDA approval July-August: MAA submission late Q4- early 2027: FDA approval
0 · Reply
Finnish_boy
Finnish_boy Jan. 15 at 4:02 PM
$PYPD US partnership will be annoinced around NDA submission (March). Enough cash until FDA approval😍. What a setup. PT April $10. January-February nice time to buy more shares if SP stays under $5. Stock should be now already $10 !!
3 · Reply
Qesim
Qesim Jan. 15 at 4:00 PM
$PYPD Partnership in a matter of weeks.
0 · Reply
Finnish_boy
Finnish_boy Jan. 15 at 9:53 AM
$PYPD Today call. I will post if there is some new info.
0 · Reply
Finnish_boy
Finnish_boy Jan. 15 at 9:52 AM
$PYPD US partnership deal most likely in February, at the latest March. I was too early telling it's the matter of couple of weeks but when there is now multiple potential partners negotiating, that means bigger deal ! So patience now, and you will rewarded in a big way already in 2-3 months (US partnership + NDA submission)
1 · Reply
Finnish_boy
Finnish_boy Jan. 14 at 12:07 PM
$PYPD Phone app free. https://web.quartr.com/link/companies/17671/events/541547?targetTime=null
0 · Reply
Finnish_boy
Finnish_boy Jan. 14 at 11:56 AM
$PYPD
0 · Reply
Finnish_boy
Finnish_boy Jan. 12 at 5:31 PM
$PYPD 3 month target price: $10 !!
0 · Reply
Finnish_boy
Finnish_boy Jan. 12 at 5:29 PM
$PYPD Tomorrow event 👍we can hear hints about US partnership deal. Maybe they remind also about GLP-1 data and how they are progressing NDA submission. I think they will sign a deal with big med-device company Medtronic, J&J or BD in 1-7 weeks !! Buckle up !!
2 · Reply
pandodark
pandodark Jan. 12 at 2:49 PM
$PYPD At $10 this would only have a $150 market cap. Think this is going to be shockingly higher.
0 · Reply
Finnish_boy
Finnish_boy Jan. 11 at 4:58 PM
$PYPD My best guess Polypid signs partnership deal with Medtronic or J&J or BD within 1-7 weeks (Jan-Feb). I am buying more shares tomorrow.
1 · Reply
Finnish_boy
Finnish_boy Jan. 11 at 10:58 AM
$PYPD IMHO stock is crazy opportunity under $5 levels or around $5. There are risks e.g regulatory (NDA, FDA approval process), manufacturing (FDA inspection), and profitability. I think stock goes over $10 levels this year and long-term potential is crazy big also. Lets see.🤑
0 · Reply
Finnish_boy
Finnish_boy Jan. 11 at 10:45 AM
$PYPD Current facility enough for 5 years ahead from commercial launch. The second facility will be build in US⬇️The opportunity of developing and growing pipeline is huge so they want to do that totally by themselves.
0 · Reply
Finnish_boy
Finnish_boy Jan. 11 at 10:44 AM
$PYPD COO about potential US partner: Either the hospital anti-infective companies or big med-device companies Medtronic, J&J, and Becton Dickinson. Told that med-device companies not as straightforward but more relevant for PYPD. I think they sign a deal with some of the med-device companies in 1-7 weeks.
0 · Reply
Finnish_boy
Finnish_boy Jan. 11 at 10:29 AM
$PYPD Their goal is to be a big company. They are not trying to sell the company. Opportunity developing pipeline is so big. Their technology can be used everywhere (systematic vs local, look at picture, huge difference). But at first they will partner with DPLEX100 abdominal to get things going on. And they already have EU partner for that.
0 · Reply
Finnish_boy
Finnish_boy Jan. 10 at 2:31 PM
$PYPD ⏳
0 · Reply
DASmyth
DASmyth Jan. 8 at 4:09 PM
$PYPD With such a low float (8 million), this baby could shoot to $30 with NDA and partnership news.
1 · Reply
Project_Profit
Project_Profit Jan. 8 at 3:35 PM
$PYPD curious if they may try and get off pink sheets and get listed on NASDAQ since their IP is likely to be massively transformative. It would open up a lot of institutions to own this IP....
1 · Reply
Finnish_boy
Finnish_boy Jan. 7 at 9:02 PM
$PYPD New logo, new websites, new era.
1 · Reply
Finnish_boy
Finnish_boy Jan. 7 at 8:02 PM
$PYPD Time for rebranding also. US partnership news in a month!!
0 · Reply
Finnish_boy
Finnish_boy Jan. 7 at 8:01 PM
$PYPD Buckle up! https://x.com/i/status/2008984906492452959
0 · Reply